5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.94▲ | 2.94▲ | 2.95▲ | 3.04▼ | 3.10▼ |
MA10 | 2.97▼ | 2.99▼ | 3.00▼ | 3.07▼ | 3.11▼ |
MA20 | 3.02▼ | 3.04▼ | 3.05▼ | 3.11▼ | 3.08▼ |
MA50 | 3.07▼ | 3.08▼ | 3.09▼ | 3.12▼ | N/A |
MA100 | 3.12▼ | 3.12▼ | 3.10▼ | 3.05▼ | N/A |
MA200 | 3.12▼ | 3.16▼ | 3.12▼ | 3.04▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.009▼ | -0.010▼ | -0.013▼ | -0.016▼ | 0.018▲ |
RSI | 40.814▼ | 41.494▼ | 38.297▼ | 39.490▼ | 49.276▼ |
STOCH | 7.543▼ | 4.762▼ | 6.044▼ | 29.827 | 37.728 |
WILL %R | -74.286 | -74.286 | -78.049▼ | -82.051▼ | -80.796▼ |
CCI | -39.719 | -52.836 | -70.873 | -221.667▼ | -112.041▼ |
CDL | $GRCE Harami Candlestick Pattern Detected | Set Alert |
Tuesday, September 23, 2025 07:17 AM
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech ...
|
Monday, September 22, 2025 05:17 AM
Presentation Highlighted Data Supporting Clinical Benefit of GTx-104 Compared to Orally Administered Nimodipine in the Treatment of aneurysmal Subarachnoid Hemorrhage (aSAH)PRINCETON, N.J., Sept. 22, ...
|
Friday, July 01, 2022 05:00 PM
Short interest in Grace Therapeutics Inc (NASDAQ:GRCE) increased during the last reporting period, rising from 80.17K to 130.84K. This put 1.14% of the company's publicly available shares short.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
30/09/25 | 3.01 | 3.01 | 2.91 | 2.98 | 48,100 |
29/09/25 | 3.10 | 3.10 | 2.96 | 2.97 | 102,800 |
26/09/25 | 3.07 | 3.11 | 3.04 | 3.09 | 29,100 |
25/09/25 | 3.12 | 3.12 | 3.01 | 3.08 | 85,100 |
24/09/25 | 3.07 | 3.14 | 3.07 | 3.10 | 71,973 |
23/09/25 | 3.11 | 3.11 | 3.06 | 3.11 | 61,100 |
22/09/25 | 3.12 | 3.14 | 3.08 | 3.11 | 46,700 |
19/09/25 | 3.09 | 3.13 | 3.08 | 3.10 | 40,700 |
18/09/25 | 3.10 | 3.18 | 3.06 | 3.12 | 167,300 |
17/09/25 | 3.09 | 3.14 | 3.04 | 3.06 | 60,800 |
|
|
||||
|
|
||||
|
|